---
schema_version: "secwatch.filing_event.v1"
accession: "0001157523-22-001485"
form_type: "8-K"
ticker: "CCRN"
cik: "0001141103"
company_name: "CROSS COUNTRY HEALTHCARE INC"
filed_at: "2022-11-02T23:59:59+00:00"
generated_at: "2026-06-22T12:08:43.154940+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Cross Country Healthcare Q3 revenue $636.1M (+70% YoY); guides Q4 revenue $590-600M

## Summary
- Revenue $636.1M (+70% YoY, -16% sequential); net income $34.8M ($0.93 diluted EPS).
- Adjusted EBITDA $63.8M (10.0% margin), down 24% sequentially from $83.5M.
- Repurchased 1M shares for $24.3M at avg $23.97; $87.2M remaining under $100M buyback.
- Q4 guidance: Revenue $590-600M (down 6-8% YoY); Adjusted EPS $0.85-$0.95.
- Cash from ops $140.6M; closed Mint and Lotus locum tenens acquisitions in October.

## SEC filing metadata
- accession: 0001157523-22-001485
- form_type: 8-K
- ticker: CCRN
- cik: 0001141103
- company_name: CROSS COUNTRY HEALTHCARE INC
- filed_at: 2022-11-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1141103/000115752322001485/0001157523-22-001485-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1141103/000115752322001485/a52957594.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001157523-22-001485
- JSON: https://secwatch.observer/filing/0001157523-22-001485.json
- Plain text: https://secwatch.observer/filing/0001157523-22-001485.txt

## Key facts
- Earnings Releases
  CROSS COUNTRY HEALTHCARE INC reported the third quarter ended September 30, 2022 results: revenue $636,098, net income $34,793, EPS $0.93.
  - Period: the third quarter ended September 30, 2022
  - Revenue: $636,098
  - Net income: $34,793
  - EPS: $0.93
  - Result: reported results
  source text: September 30, 2022. SELECTED FINANCIAL INFORMATION: Variance Variance Q3 2022 vs Q3 2022 vs Dollars are in thousands, except per share amounts Q3 2022 Q3 2021 Q2 2022 Revenue $ 636,098 70 % (16) % Gross profit margin* 22.6 % 20 bps — bps Net income attributable to common stockholders $ 34,793 48 % (34) % Diluted EPS $ 0.93 $ 0.31 $ (0.47) Adjusted EBITDA* $
  evidence_url: https://www.sec.gov/Archives/edgar/data/1141103/000115752322001485/0001157523-22-001485-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.